Additionally, deletion of SLFN5 triggers enhanced expression of ISGs, resulting in greater antitumor activity, as observed in GBM patient-derived cell lines grown as neurospheres under stem cell permissive conditions. This evidence concerns the gene SLFN5 and glioblastoma.